{"id":30554,"date":"2023-01-26T18:45:43","date_gmt":"2023-01-26T18:45:43","guid":{"rendered":"https:\/\/dailytalks.org\/?p=30554"},"modified":"2023-01-26T18:45:43","modified_gmt":"2023-01-26T18:45:43","slug":"recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=30554","title":{"rendered":"Recombinant Adeno-Associated Virus (rAAV) Technology  Pioneered by AskBio\u2019s Dr. Jude Samulski is Key Component  of All FDA Approved AAV Gene Therapeutics"},"content":{"rendered":"<p>Research Triangle Park, N.C. (December 20, 2022) &#8211; Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA\u2019s approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder&#8230;<br \/><a href=\"https:\/\/www.bayer.com\/media\/en-us\/recombinant-adeno-associated-virus-raav-technology--pioneered-by-askbios-dr-jude-samulski-is-key-component--of-all-fda-approved-aav-gene-therapeutics\/\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Research Triangle Park, N.C. (December 20, 2022) &#8211; Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and<\/p>\n","protected":false},"author":1,"featured_media":30555,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[],"class_list":["post-30554","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-tech"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics.jpg",1200,630,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-300x158.jpg",300,158,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-768x403.jpg",640,336,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-1024x538.jpg",640,336,true],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics.jpg",1200,630,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics.jpg",1200,630,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-1024x538.jpg",1024,538,true],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2023\/01\/30554-recombinant-adeno-associated-virus-raav-technology-pioneered-by-askbios-dr-jude-samulski-is-key-component-of-all-fda-approved-aav-gene-therapeutics-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=35\" rel=\"category\">Tech<\/a>","tag_info":"Tech","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/30554","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=30554"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/30554\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/30555"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=30554"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=30554"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=30554"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}